Take stock of global drug sales in 2019 Top 100.

As the world's major pharmaceutical companies release their 2019 annual reports, the latest top 100 list of global drug sales is out.
statistics show that the top 100 threshold has exceeded $1.4 billion, up more than 10 percent from last year, and top100 sales reached $337 billion, up about 7 percent from last year, reflecting the rapid growth of the global drug market.
this year's global "drug king" is still AbbVie's anti-TNF alpha monoantigen Humira ® (Sumira ®), which is also its 8th consecutive year of joint sales champion.
affected by the expiration of patents in Europe and other regions, its sales fell 3.85 percent from last year to $19,169 million, and the impact of the $20 billion mark again failed, which should be its last chance, in the next few years its sales will continue to decline, but not to fall, because in its main market, the United States, AbbVie has a series of patent protection, won almost all patent protection, so that it can be protected in the next few years.
drug on the list has sales of more than $10 billion, the first time in history that Keytruda ® is growing at an annual rate of more than 50 percent and is on track to hit Humira ® in the coming years.
the top 10 threshold is approaching the $7 billion mark.
from the point of view of adaptive diseases, tumors, autoimmune diseases, diabetes, cardiovascular diseases, viral infections, etc. are still the field of frequent best-selling drugs.
In terms of drug types, distribution is more balanced and diversified, with chemical and biological drugs accounting for almost half of the total, and new mechanisms, structures and types of drugs have emerged, reflecting the fact that only continuous innovation can occupy a high ground in the competition in the drug market.
from the company's point of view, the list is almost monopolized by the European and American Japanese pharmaceutical companies, the best-selling drug value sources in addition to innovative and drug promotion, including the expansion of new indications and to different regions, in these two aspects of China's pharmaceutical companies and European and American giants there is not a small gap, but with the rise of a large number of innovative pharmaceutical companies represented by Hengrui, this list should soon be able to see the name of Chinese companies.
2019 Global Drug Sales TOP100 Data Source: Company Statements, settlement is not in U.S. dollars, calculated at the exchange rate at the time the statement was published;